Role of alosetron in IBS

What is the role of alosetron in IBS? 

Although alosetron was approved in 2000 by the Food and Drug Administration (FDA) in the United States for adult women with IBS-D, it was removed from the market later that year because of concerns about its safety, particularly severe constipation and ischemic colitis. However, as a result of public demand, the FDA in June 2002 reinstated alosetron for women with chronic, severe IBS-D unresponsive to conventional therapy. This required adherence to the manufacturer’s prescribing program starting at a lower dose of 0.5 mg twice daily. This lower dose has been shown to be effective in achieving global improvement in bowel symptoms for women with severe IBS-D and produces less constipation, although the risk of ischemic colitis is similar (approximately 1 in 750-1000 patients).


Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information